1
|
Klingemann H. Viscum album (mistletoe) extract for dogs with cancer? Front Vet Sci 2024; 10:1285354. [PMID: 38234984 PMCID: PMC10793657 DOI: 10.3389/fvets.2023.1285354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Accepted: 11/09/2023] [Indexed: 01/19/2024] Open
Abstract
Compared with the options available to human patients with cancer, treatment choices for dogs are often more limited. Chemotherapy is frequently the first-line treatment for many cancers. However, its efficacy can be limited, and its side effects can affect the quality of the remaining life. This paper briefly summarizes the experience with Viscum album L. (mistletoe) extract in human patients as a stipulation to consider treatment with mistletoe extract for canines with cancer. The mistletoe extract contains -among others - lectins and viscotoxins that have documented anti-proliferative effect on cancer cells as well as immune-stimulatory function. Importantly, it also improves the well-being of patients with cancer due to its lectin ML-1 content, which can trigger the release of endorphins. Being cross-reactive with canine cells and having a relatively low side effect profile, it raises the question of whether mistletoe preparations might be considered as part of the treatment approach for dogs with cancer.
Collapse
Affiliation(s)
- Hans Klingemann
- No Longer Running Behind Foundation, Boston, MA, United States
| |
Collapse
|
2
|
Park YR, Jee W, Park SM, Kim SW, Bae H, Jung JH, Kim H, Kim S, Chung JS, Jang HJ. Viscum album Induces Apoptosis by Regulating STAT3 Signaling Pathway in Breast Cancer Cells. Int J Mol Sci 2023; 24:11988. [PMID: 37569363 PMCID: PMC10418465 DOI: 10.3390/ijms241511988] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 07/24/2023] [Accepted: 07/25/2023] [Indexed: 08/13/2023] Open
Abstract
In this study, we investigated the potential anticancer effects of Viscum album, a parasitic plant that grows on Malus domestica (VaM) on breast cancer cells, and explored the underlying mechanisms. VaM significantly inhibited cell viability and proliferation and induced apoptosis in a dose-dependent manner. VaM also regulated cell cycle progression and effectively inhibited activation of the STAT3 signaling pathway through SHP-1. Combining VaM with low-dose doxorubicin produced a synergistic effect, highlighting its potential as a promising therapeutic. In vivo, VaM administration inhibited tumor growth and modulated key molecular markers associated with breast cancer progression. Overall, our findings provide strong evidence for the therapeutic potential of VaM in breast cancer treatment and support further studies exploring clinical applications.
Collapse
Affiliation(s)
- Ye-Rin Park
- College of Korean Medicine, Kyung Hee University, 24, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea; (Y.-R.P.); (W.J.); (S.-M.P.); (S.W.K.); (H.B.); (J.H.J.); (H.K.)
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Wona Jee
- College of Korean Medicine, Kyung Hee University, 24, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea; (Y.-R.P.); (W.J.); (S.-M.P.); (S.W.K.); (H.B.); (J.H.J.); (H.K.)
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
| | - So-Mi Park
- College of Korean Medicine, Kyung Hee University, 24, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea; (Y.-R.P.); (W.J.); (S.-M.P.); (S.W.K.); (H.B.); (J.H.J.); (H.K.)
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Seok Woo Kim
- College of Korean Medicine, Kyung Hee University, 24, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea; (Y.-R.P.); (W.J.); (S.-M.P.); (S.W.K.); (H.B.); (J.H.J.); (H.K.)
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Hanbit Bae
- College of Korean Medicine, Kyung Hee University, 24, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea; (Y.-R.P.); (W.J.); (S.-M.P.); (S.W.K.); (H.B.); (J.H.J.); (H.K.)
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Ji Hoon Jung
- College of Korean Medicine, Kyung Hee University, 24, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea; (Y.-R.P.); (W.J.); (S.-M.P.); (S.W.K.); (H.B.); (J.H.J.); (H.K.)
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
| | - Hyungsuk Kim
- College of Korean Medicine, Kyung Hee University, 24, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea; (Y.-R.P.); (W.J.); (S.-M.P.); (S.W.K.); (H.B.); (J.H.J.); (H.K.)
- Department of Korean Rehabilitation Medicine, Kyung Hee University Medical Center, Seoul 02447, Republic of Korea
| | - Sangki Kim
- Dalim Biotech, 33 Sinpyeong-ro, Jijeong-myeon, Wonju-si 26348, Republic of Korea; (S.K.); (J.S.C.)
| | - Jong Sup Chung
- Dalim Biotech, 33 Sinpyeong-ro, Jijeong-myeon, Wonju-si 26348, Republic of Korea; (S.K.); (J.S.C.)
| | - Hyeung-Jin Jang
- College of Korean Medicine, Kyung Hee University, 24, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea; (Y.-R.P.); (W.J.); (S.-M.P.); (S.W.K.); (H.B.); (J.H.J.); (H.K.)
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea
| |
Collapse
|
3
|
In Vivo Analysis of Extract of Leaves of Mistletoe as a Benalu Duku: Clinical Chemical Value Associated with Histopathology, Liver, Kidneys, and Lethal Dose Determinate. Vet Med Int 2022; 2022:1182866. [PMID: 36544714 PMCID: PMC9763007 DOI: 10.1155/2022/1182866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2022] [Revised: 10/23/2022] [Accepted: 11/25/2022] [Indexed: 12/15/2022] Open
Abstract
The active compounds from the leaves of Dendrophthoe pentandra L. Miq., also known as, Benalu Duku (in Indonesia), are known to contain progesterone-like compounds (PLCs). This study aims to determine the effect of giving a single dose of PLCs on liver and kidney function in rats and the dose limit that causes the death of experimental animals. The PLCs were analyzed for chemical and physical characterization and compared to a pure standard of progesterone using HPLC, IR spectrometry, thermogravimetry, and NMR. The research was carried out in two sections. In section one, thirty-five healthy adult male rats were divided into six experimental groups and a control group of five rats each. The groups received, respectively, 50 to 75 mg/kg of PLCs (i.p.). The control group was given a 0.5 mL Aqua Pro injection. Alanine aminotransferase, aspartate aminotransferase, creatinine, and blood urea nitrogen were assessed using the clinical chemistry of blood serum analysis. Cell disruptions were analyzed to determine the degeneration effects of PLCs on the liver and kidney in the experimental and control groups. In section two, thirty healthy adult male rats were divided into 6 groups, each group of 5 rats, and injected with PLCs at a dose of 0.9-2.1 g/kg BW, followed by a lethal dose test. The control groups were available for 5 individual rats at 0 g/kg BW of PLCs. Our findings indicated that PLCs have a similarity chemical and physical characterized each other compounds, then the following administration of 50 to 75 mg/kg of PLCs did not affect the parameters of clinical chemistry. Histopathology analysis of the liver and kidney revealed normal subcellular levels in the experimental group, with the nonlethal dose at 0.9 g/kg BW.
Collapse
|
4
|
Pochet S, Lechon AS, Lescrainier C, De Vriese C, Mathieu V, Hamdani J, Souard F. Herb-anticancer drug interactions in real life based on VigiBase, the WHO global database. Sci Rep 2022; 12:14178. [PMID: 35986023 PMCID: PMC9391489 DOI: 10.1038/s41598-022-17704-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Accepted: 07/29/2022] [Indexed: 12/21/2022] Open
Abstract
AbstractCancer patients could combine herbal treatments with their chemotherapy. We consulted VigiBase, a WHO database of individual case safety reports (ICSRs) which archives reports of suspected Adverse Drug Reactions (ADRs) when herbal products are used in conjunction with anti-cancer treatment. We focused on the possible interactions between antineoplastic (L01 ATC class) or hormone antagonists (L02B ATC class) with 10 commonly used herbs (pineapple, green tea, cannabis, black cohosh, turmeric, echinacea, St John’s wort, milk thistle and ginger) to compare ADRs described in ICSRs with the literature. A total of 1057 ICSRs were extracted from the database but only 134 were complete enough (or did not concern too many therapeutic lines) to keep them for analysis. Finally, 51 rationalizable ICSRs could be explained, which led us to propose a pharmacokinetic or pharmacodynamic interaction mechanism. Reports concerned more frequently women and half of the rationalizable ICSRs involved Viscum album and Silybum marianum. 5% of the ADRs described could have been avoided if clinicians had had access to the published information. It is also important to note that in 8% of the cases, the ADRs observed were life threatening. Phytovigilance should thus be considered more by health care professionals to best treat cancer patients and for better integrative care.
Collapse
|
5
|
Loef M, Walach H. Survival of Cancer Patients Treated with Non-Fermented Mistletoe Extract: A Systematic Review and Meta-Analysis. Integr Cancer Ther 2022; 21:15347354221133561. [PMID: 36324298 PMCID: PMC9634211 DOI: 10.1177/15347354221133561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Background: Mistletoe extracts (ME) are used in integrative cancer care to improve
quality of life and to prolong survival. ME are available from different
producers and differ in pharmaceutical processing, such as fermentation. In
contrast to fermented ME, the impact of unfermented extracts on the survival
of cancer patients has not yet been assessed in a meta-analysis. Methods: We searched the databases Embase, CENTRAL, Europe PMC, Clinicaltrials.gov,
Opengrey and Google Scholar, and selected controlled studies on cancer
patients treated with non-fermented ME. We included randomized controlled
trials (RCTs) and non-randomized studies of intervention (NRSIs). The risk
of bias was assessed with Cochrane’s ROB2 and ROBINS-I; a meta-analysis was
conducted. Results: Eleven RCTs and eight NRSIs met the inclusion criteria. The studies were
heterogeneous and their ROB2 and ROBINS-I displayed a moderate and high risk
of bias, respectively. For RCTs, the pooled effect estimate of non-fermented
ME on survival was HR = 0.81 (95% CI 0.69-0.95, P = .01).
Subgroup analyses as well as the NRSIs estimation support the robustness of
the finding. When active comparators are added to the analysis, the effect
estimates become non-significant. Conclusion: The results may indicate a positive impact of non-fermented ME on the overall
survival of cancer patients. High quality RCTs are necessary to substantiate
our results. Prospero Registration: CRD42021233177
Collapse
Affiliation(s)
| | - Harald Walach
- CHS-Institute, Berlin, Germany.,Next Society Institute, Kazimieras Simonavicius University, Vilnius, Lithuania
| |
Collapse
|
6
|
Vanhaverbeke C, Touboul D, Elie N, Prévost M, Meunier C, Michelland S, Cunin V, Ma L, Vermijlen D, Delporte C, Pochet S, Le Gouellec A, Sève M, Van Antwerpen P, Souard F. Untargeted metabolomics approach to discriminate mistletoe commercial products. Sci Rep 2021; 11:14205. [PMID: 34244531 PMCID: PMC8270909 DOI: 10.1038/s41598-021-93255-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2021] [Accepted: 06/17/2021] [Indexed: 01/25/2023] Open
Abstract
Mistletoe (Viscum album L.) is used in German-speaking European countries in the field of integrative oncology linking conventional and complementary medicine therapies to improve quality of life. Various companies sell extracts, fermented or not, for injection by subcutaneous or intra-tumoral route with a regulatory status of anthroposophic medicinal products (European Medicinal Agency (EMA) assessment status). These companies as well as anthroposophical physicians argue that complex matrices composed of many molecules in mixture are necessary for activity and that the host tree of the mistletoe parasitic plant is the main determining factor for this matrix composition. The critical point is that parenteral devices of European mistletoe extracts do not have a standard chemical composition regulated by EMA quality guidelines, because they are not drugs, regulatory speaking. However, the mechanism of mistletoe's anticancer activity and its effectiveness in treating and supporting cancer patients are not fully understood. Because of this lack of transparency and knowledge regarding the matrix chemical composition, we undertook an untargeted metabolomics study of several mistletoe extracts to explore and compare their fingerprints by LC-(HR)MS(/MS) and 1H-NMR. Unexpectedly, we showed that the composition was primarily driven by the manufacturer/preparation method rather than the different host trees. This differential composition may cause differences in immunostimulating and anti-cancer activities of the different commercially available mistletoe extracts as illustrated by structure-activity relationships based on LC-MS/MS and 1H-NMR identifications completed by docking experiments. In conclusion, in order to move towards an evidence-based medicine use of mistletoe, it is a priority to bring rigor and quality, chemically speaking.
Collapse
Affiliation(s)
| | - David Touboul
- Université Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, 91198, Gif-sur-Yvette, France
| | - Nicolas Elie
- Université Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, 91198, Gif-sur-Yvette, France
| | - Martine Prévost
- Structure et Fonction des Membranes Biologiques, Université libre de Bruxelles (ULB), 1050, Brussels, Belgium
| | - Cécile Meunier
- CHU Grenoble Alpes, Service de Biochimie et Biologie moléculaire et Toxicologie Environnementale, 38000, Grenoble, France
| | - Sylvie Michelland
- Univ. Grenoble Alpes, CHU Grenoble Alpes, Plateforme GExiM, 38000, Grenoble, France
- Univ. Grenoble Alpes, CNRS, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG, Grenoble, France
| | - Valérie Cunin
- Univ. Grenoble Alpes, CHU Grenoble Alpes, Plateforme GExiM, 38000, Grenoble, France
- Univ. Grenoble Alpes, CNRS, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG, Grenoble, France
| | - Ling Ma
- Department of Pharmacotherapy and Pharmaceutics (DPP), Université libre de Bruxelles (ULB), 1050, Brussels, Belgium
- Institute for Medical Immunology, Université libre de Bruxelles, 6041, Gosselies, Belgium
- ULB Center for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Brussels, Belgium
| | - David Vermijlen
- Department of Pharmacotherapy and Pharmaceutics (DPP), Université libre de Bruxelles (ULB), 1050, Brussels, Belgium
- Institute for Medical Immunology, Université libre de Bruxelles, 6041, Gosselies, Belgium
- ULB Center for Research in Immunology (U-CRI), Université libre de Bruxelles (ULB), Brussels, Belgium
| | - Cédric Delporte
- RD3-Pharmacognosy, Bioanalysis and Drug Discovery and Analytical Platform of the Faculty of Pharmacy, Université libre de Bruxelles (ULB), 1050, Brussels, Belgium
| | - Stéphanie Pochet
- Department of Pharmacotherapy and Pharmaceutics (DPP), Université libre de Bruxelles (ULB), 1050, Brussels, Belgium
| | - Audrey Le Gouellec
- CHU Grenoble Alpes, Service de Biochimie et Biologie moléculaire et Toxicologie Environnementale, 38000, Grenoble, France
- Univ. Grenoble Alpes, CHU Grenoble Alpes, Plateforme GExiM, 38000, Grenoble, France
- Univ. Grenoble Alpes, CNRS, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG, Grenoble, France
| | - Michel Sève
- Univ. Grenoble Alpes, CHU Grenoble Alpes, Plateforme GExiM, 38000, Grenoble, France
- Univ. Grenoble Alpes, CNRS, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG, Grenoble, France
| | - Pierre Van Antwerpen
- RD3-Pharmacognosy, Bioanalysis and Drug Discovery and Analytical Platform of the Faculty of Pharmacy, Université libre de Bruxelles (ULB), 1050, Brussels, Belgium
| | - Florence Souard
- Univ. Grenoble Alpes, CNRS, DPM, 38000, Grenoble, France
- Department of Pharmacotherapy and Pharmaceutics (DPP), Université libre de Bruxelles (ULB), 1050, Brussels, Belgium
| |
Collapse
|
7
|
Kabelitz D. Gamma Delta T Cells (γδ T Cells) in Health and Disease: In Memory of Professor Wendy Havran. Cells 2020; 9:cells9122564. [PMID: 33266147 PMCID: PMC7760329 DOI: 10.3390/cells9122564] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2020] [Accepted: 11/25/2020] [Indexed: 11/27/2022] Open
Affiliation(s)
- Dieter Kabelitz
- Institute of Immunology, Christian-Albrechts University of Kiel, D-24105 Kiel, Germany
| |
Collapse
|
8
|
Papadopoulou M, Sanchez Sanchez G, Vermijlen D. Innate and adaptive γδ T cells: How, when, and why. Immunol Rev 2020; 298:99-116. [PMID: 33146423 DOI: 10.1111/imr.12926] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 09/03/2020] [Indexed: 12/13/2022]
Abstract
γδ T cells comprise the third cell lineage of lymphocytes that use, like αβ T cells and B cells, V(D)J gene rearrangement with the potential to generate a highly diverse T cell receptor (TCR) repertoire. There is no obvious conservation of γδ T cell subsets (based on TCR repertoire and/or function) between mice and human, leading to the notion that human and mouse γδ T cells are highly different. In this review, we focus on human γδ T cells, building on recent studies using high-throughput sequencing to analyze the TCR repertoire in various settings. We make then the comparison with mouse γδ T cell subsets highlighting the similarities and differences and describe the remarkable changes during lifespan of innate and adaptive γδ T cells. Finally, we propose mechanisms contributing to the generation of innate versus adaptive γδ T cells. We conclude that key elements related to the generation of the γδ TCR repertoire and γδ T cell activation/development are conserved between human and mice, highlighting the similarities between these two species.
Collapse
Affiliation(s)
- Maria Papadopoulou
- Department of Pharmacotherapy and Pharmaceutics, Université Libre de Bruxelles (ULB), Brussels, Belgium.,Institute for Medical Immunology (IMI), Université Libre de Bruxelles (ULB), Gosselies, Belgium.,ULB Center for Research in Immunology (U-CRI), Belgium
| | - Guillem Sanchez Sanchez
- Department of Pharmacotherapy and Pharmaceutics, Université Libre de Bruxelles (ULB), Brussels, Belgium.,Institute for Medical Immunology (IMI), Université Libre de Bruxelles (ULB), Gosselies, Belgium.,ULB Center for Research in Immunology (U-CRI), Belgium
| | - David Vermijlen
- Department of Pharmacotherapy and Pharmaceutics, Université Libre de Bruxelles (ULB), Brussels, Belgium.,Institute for Medical Immunology (IMI), Université Libre de Bruxelles (ULB), Gosselies, Belgium.,ULB Center for Research in Immunology (U-CRI), Belgium
| |
Collapse
|